TECX · XBRL financial data
Tectonic Therapeutic financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (TECX's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Research and development | 87,236 | 83,114 | 72,186 | 47,700 | 41,364 | 63,489 |
| General and administrative | 32,992 | 35,727 | 33,248 | 23,967 | 16,651 | 20,547 |
| Total operating expenses | 120,228 | 118,841 | 105,434 | 71,667 | 58,015 | 84,036 |
| Operating income (loss) | (120,228) | (118,841) | (105,434) | 10,192 | (58,015) | (84,036) |
| Interest income | 719 | — | — | 581 | 4,261 | 11,297 |
| Interest expense | — | 203 | 1,808 | 152 | 107 | 63 |
| Other income (expense) | — | — | — | 396 | (511) | (119) |
| Income tax expense (benefit) | — | — | 0 | 377 | 0 | 1,230 |
| Net income (loss) | (119,712) | (119,126) | (105,890) | 12,157 | (57,982) | (74,151) |
| Earnings per share, basic‡ USD per share | — | (5.25) | (4.57) | 0.51 | (6.83) | (4.05) |
| Earnings per share, diluted‡ USD per share | — | (5.25) | (4.57) | 0.51 | (6.83) | (4.05) |
| Weighted average shares, basic‡ thousands of shares | — | 23 | 23 | 23,493 | 8,490 | 18,323 |
| Weighted average shares, diluted‡ thousands of shares | — | 23 | 23 | 23,621 | 8,490 | 18,323 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-1.8867924528301885 stock split (June 2024); filings made before it reported them unadjusted.
Balance sheet
CSVFiscal years (TECX's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 259,682 | 189,567 | 92,563 | 98,020 | 141,239 | 253,798 |
| Prepaid and other current assets | 7,560 | 9,578 | 7,112 | 1,958 | 5,618 | 2,974 |
| Total current assets | 267,242 | 199,145 | 99,958 | 100,261 | 146,857 | 257,359 |
| Property and equipment, net | 3,064 | 4,126 | 2,894 | 0 | 2,151 | 1,185 |
| Right-of-use asset | — | 0 | 1,057 | 432 | 2,235 | 874 |
| Total assets | 271,234 | 203,837 | 103,949 | 101,093 | 152,905 | 261,038 |
| Accounts payable | 2,682 | 3,486 | 384 | 27 | 976 | 1,093 |
| Accrued liabilities | 13,693 | 15,638 | 11,732 | 5,449 | 7,850 | 7,340 |
| Total current liabilities | 16,614 | 19,386 | 13,115 | 6,354 | 11,610 | 9,666 |
| Lease liability, non-current | — | 0 | 188 | 0 | 132 | 0 |
| Total liabilities | 16,890 | 34,361 | 28,579 | 6,354 | 12,129 | 9,709 |
| Accumulated deficit | (264,416) | (383,542) | (489,432) | (477,275) | (148,586) | (222,737) |
| Total stockholders' equity | 254,344 | 169,476 | 75,370 | 94,739 | 140,776 | 251,329 |
| Total liabilities and equity | 271,234 | 203,837 | 103,949 | 101,093 | 152,905 | 261,038 |
| Common shares outstanding (cover page)‡ thousands of shares | 22,060 | 23,159 | 23,367 | 23,776 | 18,663 | 18,777 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-1.8867924528301885 stock split (June 2024); filings made before it reported them unadjusted.
Cash flows
CSVFiscal years (TECX's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (119,712) | (119,126) | (105,890) | 12,157 | (57,982) | (74,151) |
| Stock-based compensation | 15,628 | 18,579 | 11,522 | 6,891 | 3,491 | 10,497 |
| Depreciation and amortization | 1,207 | 1,399 | 1,440 | 617 | 1,645 | 1,375 |
| Net cash from operating activities | (98,803) | (98,025) | (97,208) | (63,190) | (59,080) | (60,078) |
| Purchases of property and equipment | 1,177 | 2,461 | 267 | 8 | 156 | 208 |
| Net cash from investing activities | (1,177) | (2,461) | (267) | 85,076 | (156) | (138) |
| Proceeds from issuing common stock | — | — | 204 | 86 | — | — |
| Proceeds from issuing equity | — | — | — | — | — | 400,000 |
| Proceeds from long-term debt | — | 15,000 | 0 | — | — | — |
| Net cash from financing activities | 172,619 | 30,371 | 262 | (16,029) | 171,714 | 173,355 |
| Net change in cash | 72,639 | (70,115) | (97,213) | 5,857 | 112,470 | 113,044 |
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Tectonic Therapeutic | 234,666 | not reported | (14,907)* | 19.9M | 12.8 quarters | 10-QSep 30, 2026 |
| Aldeyra Therapeutics | 40,975 | not reported | (4,124)* | 60.4M | — | 10-QSep 30, 2026 |
| Heron Therapeutics | 20,721 | not reported | (2,213)* | 189.9M | 19.3 quarters | 10-QJun 30, 2026 |
| Sagimet Biosciences | 165,896 | not reported | (11,099)* | not reported | 23.2 quarters | 10-QJun 30, 2026 |
| Lifecore Biomedical | 23,035 | 25,322 | 6,946* | 37.9M | — | 10-QSep 30, 2026 |
| Annexon | 199,270 | not reported | (48,007)* | not reported | 4.4 quarters | 10-QJun 30, 2026 |
| Precigen | 14,959 | 74,148 | 11,883* | 358.5M | — | 10-QSep 30, 2026 |
| SELLAS Life Sciences Group | 138,343 | not reported | (7,588)* | 201.9M | 18.2 quarters | 10-QJun 30, 2026 |
| DBV Technologies | 165,700 | 1,600 | (51,500)* | 314.4M | 3.2 quarters | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.